Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CC-92328 |
| Synonyms | |
| Therapy Description |
CC-92328 is a trispecific natural killer (NK) cell engager, which potentially leads to activation of NK cells and increased cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CC-92328 | CC 92328|CC92328 | CC-92328 is a trispecific natural killer (NK) cell engager, which potentially leads to activation of NK cells and increased cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04975399 | Phase I | CC-92328 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | Terminated | USA | ESP | CAN | 0 |